Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Background: Breast cancer is the uncontrolled, abnormal growth of malignant breast tissue affecting predominantly women. Metastatic breast cancer (mBC) is an advanced stage of the disease when the disease has spread beyond the original organ. Hormone receptor status and human epidermal growth factor...

Full description

Bibliographic Details
Main Authors: N Fleeman, A Bagust, A Boland, R Dickson, Y Dundar, M Moonan, J Oyee, M Blundell, H Davis, A Armstrong, N Thorp
Format: Article
Language:English
Published: NIHR Journals Library 2011-12-01
Series:Health Technology Assessment
Subjects:
lapatinib
trastuzumab
aromatase inhibitor
metastatic breast cancer
human epidermal growth factor receptor 2
systematic review
cost-effectiveness
clinical effectiveness
Online Access:https://doi.org/10.3310/hta15420

Internet

https://doi.org/10.3310/hta15420

Similar Items